Literature DB >> 33386968

The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients.

Shan Li1, Liangfang Shen2.   

Abstract

PURPOSE: To assess the tumor volume change after induction chemotherapy with docetaxel plus cisplatin (DP) in nasopharyngeal carcinoma (NPC).
METHODS: A total of 259 non-metastatic NPC patients who received DP induction chemotherapy were retrospectively reviewed. Gross tumor volume of nasopharynx and lymph nodes (GTVnx and GTVnd) were contoured before and after chemotherapy. Univariate and multivariate analyses were performed to identify factors associated with tumor volume reduction.
RESULTS: For GTVnx, the mean volume before and after chemotherapy were 43.2 cm3 vs 37.4 cm3 (p < 0.001) and the mean relative volume reduction was 12.7%. For GTVnd, the mean volume before and after chemotherapy were 24.6 cm3 vs 17.6 cm3 (p < 0.001) and the mean relative volume reduction was 13.9%. There was a positive linear correlation between the reduction of GTVnx and GTVnd (r = 0.351, p  < 0.001). For GTVnx volume reduction, pretreatment GTVnx volume (≤ 20 cm3 vs > 20 cm3, OR = 4.644, p = 0.001) and chemotherapy cycle (2 cycles vs 3 cycles, OR = 2.418, p = 0.009) were independently associated factors. For GTVnd volume reduction, pretreatment GTVnd volume (≤ 8 cm3 vs > 8 cm3, OR = 7.472, p < 0.001) and chemotherapy cycle (2 cycles vs 3 cycles, OR = 2.621, p = 0.007) were independently associated factors.
CONCLUSION: DP induction chemotherapy reduces tumor volumes moderately in NPC. Larger pre-treatment tumor volumes and three cycles of chemotherapy are associated with higher likelihood of tumor volume reduction.

Entities:  

Keywords:  Cisplatin; Docetaxel; Induction chemotherapy; Nasopharyngeal carcinoma; Tumor volume

Mesh:

Substances:

Year:  2021        PMID: 33386968     DOI: 10.1007/s00405-020-06477-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  21 in total

1.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

Authors:  M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control.

Authors:  Wai-Man Sze; Anne W M Lee; Tsz-Kok Yau; Rebecca M W Yeung; Kam-Ying Lau; Samuel K C Leung; Albert W M Hung; Michael C H Lee; Rick Chappell; Kuen Chan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

3.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Authors:  Ying Sun; Wen-Fei Li; Nian-Yong Chen; Ning Zhang; Guo-Qing Hu; Fang-Yun Xie; Yan Sun; Xiao-Zhong Chen; Jin-Gao Li; Xiao-Dong Zhu; Chao-Su Hu; Xiang-Ying Xu; Yuan-Yuan Chen; Wei-Han Hu; Ling Guo; Hao-Yuan Mo; Lei Chen; Yan-Ping Mao; Rui Sun; Ping Ai; Shao-Bo Liang; Guo-Xian Long; Bao-Min Zheng; Xing-Lai Feng; Xiao-Chang Gong; Ling Li; Chun-Ying Shen; Jian-Yu Xu; Ying Guo; Yu-Ming Chen; Fan Zhang; Li Lin; Ling-Long Tang; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 41.316

4.  Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.

Authors:  R L Hong; C F Hsiao; L L Ting; J Y Ko; C W Wang; J T C Chang; P J Lou; H M Wang; M H Tsai; S C Lai; T W Liu
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

5.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.

Authors:  Edwin P Hui; Brigette B Ma; Sing F Leung; Ann D King; Frankie Mo; Michael K Kam; Brian K Yu; Samuel K Chiu; Wing H Kwan; Rosalie Ho; Iris Chan; Anil T Ahuja; Benny C Zee; Anthony T Chan
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

6.  The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis.

Authors:  Xuan Li; Danian Dai; Bo Chen; Hailin Tang; Xiaoming Xie; Weidong Wei
Journal:  J Cancer       Date:  2018-02-12       Impact factor: 4.207

7.  Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.

Authors:  Li Zheng; Wenjun Liao; Peng Xu; Baisen Li; Hao Wen; Shichuan Zhang
Journal:  Med Sci Monit       Date:  2018-11-08

8.  Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer.

Authors:  Javier Cuello-López; Ana Fidalgo-Zapata; Laura López-Agudelo; Elsa Vásquez-Trespalacios
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

9.  Survival nomograms for stage III colorectal cancer.

Authors:  Chenglong Li; Qian Pei; Hong Zhu; Fengbo Tan; Zhongyi Zhou; Yuan Zhou; Yuqiang Li; Haiping Pei
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

10.  Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis.

Authors:  Wang Fangzheng; Jiang Chuner; Ye Zhimin; Sun Quanquan; Liu Tongxin; Xu Min; Wu Peng; Long Bin; Masoto Sakamoto; Wang Yuezhen; Yan Fengqin; Fu Zhenfu; Jiang Yangming
Journal:  Oncotarget       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.